Realbotix has extended the deadline for its proposed transaction to take its robotics subsidiary public on Nasdaq, giving the deal additional time to close.
In a November 9, 2026 announcement, the humanoid robotics company said the outside date for its all-stock merger between Realbotix LLC and Nasdaq-listed Onconetix has moved from November 30, 2026 to March 31, 2027. The companies now expect the transaction to close before the end of the first quarter of 2027, subject to outstanding conditions.
The amendment also removes the agreement’s minimum net cash closing condition, meaning Onconetix no longer needs to satisfy that particular cash threshold for the transaction to proceed. Realbotix said Onconetix has already advanced $3 million to Realbotix LLC.
Under the proposed structure, the robotics and AI business operated by Realbotix LLC would become Nasdaq-listed through the transaction with Onconetix. The existing Realbotix parent company expects to retain a 75% to 95% ownership stake in the business. The company said existing parent-company shareholders do not need to take action as a result of the amendment.
The listing is not complete. The merger remains subject to closing requirements, and the revised date is a contractual deadline rather than a confirmed first day of trading.
Realbotix develops humanoid robots and AI systems for social interaction, including customer-facing applications in hospitality, healthcare, education and entertainment. Its latest Echo line opened for reservations in October.
The transaction was first announced in February 2026, with subsequent updates setting earlier anticipated closing windows. The November amendment is the latest change to the timetable and terms as the company works toward a separate Nasdaq listing for its robotics subsidiary.
